The Bell Tolls For Fedratinib In A Setback For Sanofi’s Oncology Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has halted clinical trials testing its Phase III JAK2 inhibitor fedratinib after determining that the risks of treatment outweigh the benefit after cases of the neurological condition Wernicke’s encephalopathy emerged in patients.
You may also be interested in...
Sanofi Oncology Strategy: A New Lease On Cancer R&D
The company is rebooting after several late-stage setbacks in cancer R&D, relying on a collaboration with Regeneron to vault it into the field of immuno-oncology.
On The Offense: Sanofi Suits Up For A Game Change
Having exited its patent cliff and advanced several drugs into late-stage development, Sanofi is moving into a new commercial-centric phase. Its future looks bright, but success is not guaranteed.
Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term
The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.